Homotransplantation of Engineered Macrophages with Surface-Modified Nanomedicines for Mitigating Myocardial Ischemia–Reperfusion Injury
ACS Nano · 15.07.2025 · 19 (27) · 25069-25087
DOI: 10.1021/acsnano.5c05068 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 27.06.2025. Verfasst von Jiahui Cheng und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 160, Pujian Road, Pudong District, Shangh…. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Macrophages, Nanomedicine. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Program for Support of Top-notch Young Professionals, Renji Hospital, Shanghai Municipal Human Resources and Social Security Bureau.
Abstract (Originalsprache)
Immune disorders are intimately involved in the pathological progression of myocardial ischemia-reperfusion injury (MIRI) and exacerbate cardiac cell damage and mitochondria-related metabolic abnormalities. However, low-immunogenic therapeutic strategies targeting the compromised immune-metabolic microenvironment remain a major challenge. Here, we developed a syngenic reparative macrophage system for the selective delivery of nanoscale drugs by modifying liposomes loaded with nano-Pt/Se and c176 onto the surface of M2 macrophages (PS-c@M). In MIRI mice, transplanted PS-c@M was actively recruited to the myocardial ischemic region, maintained long-lasting residence, and responsively released surface-loaded nanomedicines, which in turn synergistically promoted cardiac cell survival and activated extracellular repair and angiogenesis, thus exerting long-term cardioprotective effects. Specifically, PS-c@M significantly inhibited STING-related signaling pathways, thereby remodeling the immune-inflammatory homeostasis, as evidenced by the increased proportions of M2 macrophages, reparative cardiac resident macrophages, and regulatory T cells and the decreased recruitment and infiltration of M1 macrophages and neutrophils. Moreover, PS-c@M facilitated mitochondrial oxidative phosphorylation and suppressed mitochondria-associated ferroptosis and oxidative damage. This study highlights a low-immunogenic targeted therapeutic strategy based on syngenic reparative macrophages as efficient nanomedicine carriers, with potential for development and application in a wide range of immune and inflammation-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 160, Pujian Road, Pudong District, Shanghai 200127, China.
- Department of Cardiac Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, China.
- Department of Cardiology, Shanghai Fifth People's Hospital Affiliated to Fudan University, No.801, Heqing Road, Minhang District, Shanghai 200240, China.
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Xuhui District, Shanghai 200233, China.
- Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, China.
- Department of Cardiology, Huadong Hospital Affiliated to Fudan University, No. 221, West Yan'an Road, Jing'an District, Shanghai 200240, China.
Förderung
- National Program for Support of Top-notch Young Professionals
- Renji Hospital
- Shanghai Municipal Human Resources and Social Security Bureau
- Science and Technology Commission of Shanghai Municipality
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Shanghai Shuguang Program
Zitieren
APA
Cheng, J., Gao, R., Lyu, Y., Xiong, Z., Yang, K., Zhao, X., Huang, X., Xu, L., Guo, L., Wang, W., Li, Y., Ding, W., Guo, P., Ji, Z., Li, W., Han, X., Zhang, J., Suo, S., Zhao, H., …, & Zhou, Y. (2025). Homotransplantation of Engineered Macrophages with Surface-Modified Nanomedicines for Mitigating Myocardial Ischemia–Reperfusion Injury. ACS Nano, 19(27), 25069-25087. https://doi.org/10.1021/acsnano.5c05068
Vancouver
Cheng J, Gao R, Lyu Y, Xiong Z, Yang K, Zhao X, et al. Homotransplantation of Engineered Macrophages with Surface-Modified Nanomedicines for Mitigating Myocardial Ischemia–Reperfusion Injury. ACS Nano. 2025;19(27):25069-25087. doi:10.1021/acsnano.5c05068
BibTeX
@article{Cheng2025,
author = {Cheng, Jiahui and Gao, Rifeng and Lyu, Yang and Xiong, Zhi and Yang, Kun and Zhao, Xinxin and Huang, Xiaoyu and Xu, Lingling and Guo, Linghuan and Wang, Wen and Li, Yuzhuo and Ding, Weina and Guo, Peng and Ji, Zhiqiang and Li, Wenli and Han, Xu and Zhang, Jin and Suo, Shiteng and Zhao, Huilin and Jiang, Lixian and Zhang, Qiang and Li, Bo and Wu, Lianming and Zhou, Yan},
title = {Homotransplantation of Engineered Macrophages with Surface-Modified Nanomedicines for Mitigating Myocardial Ischemia–Reperfusion Injury},
journal = {ACS Nano},
year = {2025},
volume = {19},
number = {27},
pages = {25069--25087},
doi = {10.1021/acsnano.5c05068}
}
EUVIMED